fbpx

Day

May 19, 2015
OXFORD, UK - 19 May 2015 - PsiOxus Therapeutics Ltd. (PsiOxus), the oncolytic immuno-oncology company, has closed a Series C financing round of £25 million (c$38.5 million) to progress its lead clinical candidate, enadenotucirev, and a pipeline of follow-on oncolytic programmes from the antibody 'armed' series of AbEnAd viruses.
South San Francisco, CA - May 12, 2015 - Iconic Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to translating an understanding of Tissue Factor biology to new therapeutics for retinal disease and cancer, today announced that K. Peter Hirth, PhD, co-founder and formerly Chief Executive Officer of Plexxikon, Inc., has been named a Director...
Lund, Sweden, (PRNEWSWIRE) May 13, 2015 - BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced that it has received the Frost & Sullivan 2015 Growth Capital Investment Award for outstanding achievement and superior performance in the area of technological innovation and strategic product development in...

News

DNA analysis of 442 Viking skeletons rewrites the story of Viking culture
16. September 2020
Hope that a brain injection could cure type 2 diabetes
7. September 2020
Maude has become the stereotypical migraine patient – but it’s not quite the true picture
31. July 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge